A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Bowlus, CL

http://hdl.handle.net/10026.1/19044

10.1016/j.jhep.2022.02.033
Journal of Hepatology
Elsevier

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis


PII: S0168-8278(22)00187-8
DOI: https://doi.org/10.1016/j.jhep.2022.02.033
Reference: JHEPAT 8652

To appear in: Journal of Hepatology

Received Date: 27 July 2021
Revised Date: 8 February 2022
Accepted Date: 28 February 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
Treatment with seladelpar up to 10 mg QD through 1 year resulted in robust, dose-dependent, and clinically significant improvements in biochemical markers of cholestasis and pruritus.
Title: A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis


Affiliations:

1Department of Internal Medicine, University of California, Davis, Davis, California, United States; 2Digestive Healthcare of Georgia P.C., Piedmont Atlanta Hospital, Atlanta, Georgia, United States; 3Department of Hepatology, Portsmouth Liver Centre, Portsmouth Hospitals National Health Service Trust, Queen Alexandra Hospital, Portsmouth, United Kingdom; 4Toronto Centre for Liver Disease, University Health Network and Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 5Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom; 6Outpatient Clinic, Charité, Universitätsmedizin Berlin, Berlin, Germany; 7Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan, United States; 8Radcliffe Department of Medicine, University of Oxford, United Kingdom; 9Pinnacle Clinical Research Center, San Antonio, Texas, United States; 10Department of Medicine 1, Gastroenterology, Hepatology, Pneumology and Endocrinology, Friedrich-
Alexander-University of Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany; 11Department of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland; 12Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, United States; 13Institute of Digestive Health and Liver Diseases, Mercy Medical Center, Baltimore, Maryland, United States; 14Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland; 15University of Miami Miller School of Medicine, Miami, Florida, United States; 16Department of Medicine, University of Calgary, Calgary, Alberta, Canada; 17Covenant Research, LLC, Sarasota, Florida, United States; 18Institute of Translational & Stratified Medicine, University of Plymouth and University Hospitals Plymouth National Health Service Trust, Plymouth, United Kingdom; 19Transplant Hepatology, NYU Langone Health, New York, New York, United States; 20Department of Internal Medicine I, Universitätsklinikum Tübingen, Tübingen, Germany; 21Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Palo Alto, California, United States; 22Liver Institute of Virginia, Bon Secours Mercy Health, Richmond, Virginia, United States; 23Medicine and Surgery, Baylor College of Medicine, Houston, Texas, United States; 24CymaBay Therapeutics, Inc, Newark, California, United States

**Corresponding Author:**

Christopher Bowlus, MD

University of California, Davis

One Shields Ave

Davis, CA 95616
916-734-0779

916-734-0804

clbowlus@ucdavis.edu

**Keywords:** Clinical study, Primary biliary cholangitis, Seladelpar

**Statistics:** Abstract 274 words; text, tables, references, and figure legends 6170 words; 2 tables; and 6 figures

**Conflict of Interest**

Christopher Bowlus has received grants from Arena Pharmaceuticals, Cara Therapeutics, Genfit, Genkyotex, and Novartis and grants and personal fees from CymaBay Therapeutics, Eli Lilly, Gilead, GlaxoSmithKline, and Intercept.

Michael Galambos has received consulting and investigator fees from CymaBay Therapeutics.

Richard Aspinall owns stock in CymaBay Therapeutics.

Gideon M. Hirschfield has received personal fees from CymaBay Therapeutics, Genfit, GlaxoSmithKline, HighTide, Intercept Pharma, Mirum, and Pliant.

David E. Jones has received personal fees from Abbott and Falk and personal fees and a grant from Intercept.

Stuart C. Gordon has received personal fees and advisory board compensation from CymaBay Therapeutics and research support was paid to his institution by AbbVie, Brigham and Women’s Hospital, and Genfit.

---

3
Hospital, CymaBay Therapeutics, DURECT, Eiger, Genfit, Gilead, GlaxoSmithKline, Intercept, Merck, Pliant, Shire, and Viking.

Andreas E. Kremer has received personal fees from AbbVie, Bayer, CymaBay Therapeutics, Eisai, Eli Lilly, Escient, Falk, FMC, Gilead, GlaxoSmithKline, Mirum, MSD, Myr, Newbridge, Novartis, and Zambon and personal fees and a grant from Intercept.

Marlyn J. Mayo has received consulting and investigator fees from CymaBay Therapeutics.

Paul J. Thuluvath has received a grant from CymaBay Therapeutics.

Cynthia Levy has received grants from Genkyotex, Gilead, High Tide, Intercept, Novartis, and Zydus and grants and personal fees from Cara Therapeutics, CymaBay Therapeutics, Genfit, and GlaxoSmithKline.

Mark Swain has received grants from CymaBay Therapeutics and Genfit and a grant and personal fees from Intercept.

Yvonne Dörffel, Guy Neff, David Sheridan, Carmen Stanca, Christoph Berg, and Aparna Goel have nothing to disclose.

Mitchell L. Shiffman has received grants from CymaBay Therapeutics, High Tide, and Genfit and grants and personal fees from Intercept.

John M. Vierling has received grants from Gilead, GlaxoSmithKline, and Intercept; personal fees from Intercept and Novartis; and personal fees and grants from CymaBay Therapeutics.

Pol Boudes is a former employee of CymaBay Therapeutics who owns stock in CymaBay Therapeutics and holds a patent broadly relevant to this work.

Alexandra Steinberg is a former employee of CymaBay Therapeutics who owns stock in CymaBay Therapeutics.
Yun-Jung Choi is an employee of and owns stock in CymaBay Therapeutics.

Charles McWherter is an employee of and owns stock in CymaBay Therapeutics and holds patents broadly relevant to this work.

**Financial Support Statement:** Funding for this study and manuscript preparation was provided by CymaBay Therapeutics, which had a role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

**Author Contributions**

Study concept and design: PB, AS, Y-JC, CM

Acquisition, analysis, or interpretation of data: CB, MG, RA, GMH, DEJ, YD, SCG, SAH, AEK, MJM, PJT, CL, MS, GN, DS, CS, CB, AG, MLS, JMV, PB, AS, Y-JC, CM

Drafting of the manuscript: AS, Y-JC, CM, CB, GH, CL

Critical revision of the manuscript for important intellectual content: CB, MG, RA, GMH, DEJ, YD, SCG, SAH, AEK, MJM, PJT, CL, MS, GN, DS, CS, CB, AG, MLS, JMV, PB, AS, Y-JC, CM

AS, Y-JC, CM, CB, GH, CL had access to all of the data and can vouch for the integrity of the data analyses.

**Data Availability**

Data is available from the Study Sponsor CymaBay Therapeutics. The full trial protocol can be accessed at https://www.journal-of-hepatology.eu.
ClinicalTrials.gov Number: NCT02955602

Clinicaltrialsregister.eu Number: 2016-002996-91
ABSTRACT

**Background & Aims:** We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary cholangitis (PBC) at risk for disease progression (alkaline phosphatase [ALP] ≥1.67×upper limit of normal [ULN]) receiving or intolerant to ursodeoxycholic acid.

**Methods:** In this 52-week, phase 2, dose-ranging, open-label study, patients were randomized (1:1) to seladelpar 5 (N=53) or 10 mg/day (N=55) or assigned to 2 mg/day (N=11; United Kingdom sites after interim analysis) for 12 weeks. Doses could then be uptitrated to 10 mg/day. Primary efficacy endpoint was ALP change from baseline to Week 8.

**Results:** Mean baseline ALP was 300, 345, and 295 U/L in the 2-mg, 5-mg, and 10-mg cohorts, respectively. Twenty-one percent of patients had cirrhosis, 71% had pruritus. At Week 8, mean±standard error ALP reductions from baseline were 26±2.8%, 33±2.6%, and 41±1.8% in the 2-mg (N=11), 5-mg (N=49), and 10-mg (N=52) cohorts (all p<0.005), respectively. Responses were maintained or improved at Week 52, after dose escalation in 91% and 80% of the 2-mg and 5-mg cohorts, respectively. At Week 52, composite response (ALP <1.67×ULN, ≥15% ALP decrease, and normal total bilirubin) rates were 64%, 53%, and 67%, and ALP normalization rates were 9%, 13%, and 33% in the 2-mg, 5-mg, and 10-mg cohorts, respectively. Pruritus visual analog scale score was decreased in the 5-mg and 10-mg cohorts. There were no treatment-related serious adverse events (AEs), and 4 patients discontinued due to AEs.

**Conclusions:** Seladelpar demonstrated robust, dose-dependent, clinically significant, and durable improvements in biochemical markers of cholestasis and inflammation in PBC patients.
at risk for disease progression. Seladelpar appeared safe and well tolerated with no increase in pruritus.

LAY SUMMARY

Current treatment options for patients living with primary biliary cholangitis (PBC) are not optimal due to inadequate effectiveness or undesirable side effects. Patients with PBC who took seladelpar, a new treatment being developed for PBC, at increasing doses (2, 5, or 10 mg/day) for 1 year had clinically significant, dose-dependent improvements in key liver tests. Treatment appeared safe and was not associated with any worsening in patient self-reported itch scores.
INTRODUCTION

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease predominantly afflicting middle-aged women, with approximately 1 in 1000 women over 40 years old diagnosed globally. This complex cholangiopathy is characterized by immune-mediated destruction of small intrahepatic bile ducts leading to cholestasis, with accumulation of toxic bile acids that are believed to perpetuate chronic, progressive inflammation and fibrosis, which can progress to biliary cirrhosis and liver-related death.

Elevated alkaline phosphatase (ALP) and total bilirubin are independent risk factors for decreased transplant-free survival in patients with PBC treated with first-line approved therapy, ursodeoxycholic acid (UDCA). Normalization of ALP and bilirubin levels have been proposed as ideal treatment goals. The only other approved PBC treatment is obeticholic acid (OCA), a bile acid analog and farnesoid X receptor (FXR) agonist used as a second-line add-on therapy for patients with inadequate response to UDCA or as monotherapy for those intolerant to UDCA. However, less than half of the patients treated with OCA, alone or in combination with UDCA, achieved the composite biochemical response used for its approval (ALP <1.67×upper limit of normal [ULN] and ≥15% decrease from baseline and normal total bilirubin levels). Furthermore, OCA therapy can induce or worsen pruritus in a dose-dependent manner.

Peroxisome proliferator-activated receptor (PPAR) agonists have gained attention as potential therapy for PBC and other cholestatic liver diseases. PPARδ is a broadly expressed, fatty acid-activated transcription factor involved in fatty acid metabolism and inflammation. In the liver, PPARδ-regulated genes are expressed in hepatocytes, Kupffer cells, and hepatic stellate...
Importantly, PPARδ plays a critical role in bile acid homeostasis and has antifibrotic effects.\textsuperscript{1,16-18,20}

Seladelpar is a novel, potent, selective, first-in-class PPARδ agonist being developed for the treatment of PBC in patients who do not respond to or are intolerant to UDCA.\textsuperscript{21} In a previous study, seladelpar at doses of 50 and 200 mg/day reduced ALP >60% in patients with PBC; however, 3 cases of rapid, reversible, asymptomatic elevations in hepatic aminotransferases were reported.\textsuperscript{21} Herein, we report the results of a phase 2, dose-ranging, open-label study to establish the safety and efficacy of seladelpar using 5- to 100-fold lower doses. The initial objective of this study was to assess the efficacy, safety, and tolerability of seladelpar doses up to 10 mg once daily (QD) in patients with PBC after 8 weeks of treatment. The study design was subsequently amended to examine the effects of seladelpar at 2, 5, and 10 mg QD through 12 weeks and 1 year of treatment. Efficacy endpoints focused on changes from baseline in ALP and bilirubin and other relevant liver biochemistries, including gamma-glutamyl transferase (GGT), 5'-nucleotidase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).

\textbf{PATIENTS AND METHODS}

\textbf{Patients}

Eligible patients were 18 to 75 years of age, met established diagnostic criteria\textsuperscript{5,6} for PBC, and were either UDCA intolerant or receiving stable recommended doses of UDCA for the prior 12 months. PBC diagnostic criteria\textsuperscript{5,6} included \( \geq 2 \) of the following: history of ALP >ULN for \( \geq 6 \) months, positive antimitochondrial antibody titers (\( >1:40 \) on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or positive PBC-specific antinuclear
antibodies, and liver biopsy histology consistent with PBC. Patients were also required to have ALP levels ≥1.67×ULN. Patients with compensated cirrhosis (diagnosed by liver histology, imaging tests, or liver elastography) were eligible.

Patients were excluded if they had AST or ALT levels >3×ULN; total bilirubin >2.0 mg/dL (34.2 µmol/L); total bilirubin >ULN and albumin <lower limit of normal (Rotterdam advanced stage8), except for patients with Gilbert’s syndrome (excluded if direct bilirubin >ULN; criteria in the United States (US)-specific protocol amendment); or other medical conditions that would preclude full participation or confound study results (details in Supplementary Methods).

Study design

This phase 2, international, open-label, dose-ranging, randomized study of seladelpar was conducted at 32 centers in 4 countries (Canada, Germany, United Kingdom, and the US). Enrollment began in November 2016, and the last patient completed the study in July 2019. All patients provided written informed consent. The study was approved by independent ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines.

Patients received seladelpar (CymaBay Therapeutics, Newark, California) along with UDCA at their prestudy dose levels unless they were UDCA intolerant.

Initial study design

The initial study design included an 8-week dose-ranging period followed by an 18-week extension period (Supplementary Fig. S1A). After a 2-week screening period, patients were centrally randomized (1:1 using an interactive voice/web response system) to treatment with
seladelpar 10 or 5 mg QD. A planned interim analysis was conducted after the enrollment of the 24th patient in the 10-mg and 5-mg cohorts, initially to determine whether a 25-mg cohort should be enrolled.

Amended study design

At the initial 8-week interim analysis, patients who had completed the dose-ranging treatment period had significant declines in ALP without elevations in aminotransferases. The sponsor subsequently amended the protocol to adjust the study design to add a 2-mg QD cohort (up to 18 patients), increase the dose-ranging period from 8 to 12 weeks, increase the sample size to 116, and increase the total treatment period to 52 weeks (Supplementary Fig. S1B). Since the decreases in ALP in the 10-mg cohort at that time were approaching those of the 50-mg cohort in the prior study, it was also decided not to enroll the seladelpar 25-mg cohort.

Randomization to the 5 or 10 mg QD doses continued, and after the amendment, patients at sites in the United Kingdom were registered in chronological order to treatment with seladelpar 2 mg QD for 12 weeks until the cohort was enrolled. Among patients in the 2-mg and 5-mg cohorts, beginning at Week 12 (Week 26 for patients with cirrhosis), the seladelpar dose could be titrated up to 10 mg QD based on investigator judgment for patients with an inadequate biochemical response. The seladelpar dose could be titrated down at any time during the study for safety reasons.

Study endpoints and assessments

The primary efficacy endpoint was the mean percent change in ALP from baseline at Week 8. Secondary efficacy endpoints included mean absolute and percent changes from baseline at
Weeks 12 and 52 in ALP, responder rates for a composite endpoint of ALP and total bilirubin (ALP <1.67×ULN, ≥15% decrease in ALP from baseline, and normal total bilirubin), and ALP ≤ULN. Additional secondary endpoints included changes from baseline at Weeks 12 and 52 in total and direct (conjugated) bilirubin, AST, ALT, GGT, 5´nucleotidase, lipids (as summarized in the Supplementary Methods), and pruritus intensity using a visual analog scale (VAS; 0 to 100; 0=no itch, 100=worst itch imaginable). Responder rates for published PBC response criteria were also assessed. Exploratory efficacy endpoints included change in bile acid precursor 7α-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19 (FGF19) levels from baseline.

Assessments for efficacy and safety were conducted at each study visit and at a follow-up visit 4 weeks after the end of treatment. Safety assessments included treatment-emergent adverse events (TEAEs), laboratory analyses, vital signs, physical examinations, and concomitant medications (details in Supplementary Methods).

**Statistical analysis**

The final planned sample size was 49 patients each in the 10-mg and 5-mg cohorts (increased from 12), and up to 18 in the 2-mg cohort, allowing for detection of at least a 10% mean difference in ALP percent change between the 5-mg and 10-mg cohorts with a 15% standard deviation at 90% power using a 2-sided, 2-sample t-test at α=0.05 significance level. Efficacy analyses were conducted using data from the modified intent-to-treat (mITT) population (any patient diagnosed with PBC who received ≥1 dose of seladelpar with ≥1 post-baseline ALP measurement). A sensitivity analysis on the intent-to-treat (ITT) population (any patient who received ≥1 dose of seladelpar with ≥1 post-baseline ALP measurement) was also conducted.
Safety analyses were conducted for all patients who received ≥1 dose of seladelpar (safety population). Efficacy and safety were analyzed by initial dose assignment. Select efficacy endpoints were also analyzed for patients who were randomized to seladelpar 5 mg QD and remained on this dose (5/5-mg cohort) or uptitrated to 10 mg QD (5/10-mg cohort).

Demographic and baseline characteristics were summarized using descriptive statistics for continuous variables and frequency distributions for discrete variables. Where specified, the last observation carried forward was used for missing laboratory data; other missing data were not imputed. Primary and secondary efficacy analyses were carried out using 2-sided tests at the $\alpha=0.05$ significance level. For biochemistry measures, within-group comparisons with baseline using a paired t-test were performed at Weeks 12 and 52, and pairwise comparisons of least squares (LS) means between treatment cohorts using an analysis of covariance model were performed at Weeks 8, 12, and 52. Since the seladelpar dose was uptitrated in the majority of patients in the 2-mg and 5-mg cohorts after Week 12, the differences among treatment cohorts were not reported after that time point. Responder rates were compared between treatment cohorts using Fisher’s exact test.

RESULTS

Patient disposition and baseline characteristics

Among 192 patients screened, 121 were randomized to daily oral seladelpar at doses of 2 mg (n=11), 5 mg (n=53), and 10 mg (n=55), with 11, 49, and 52 patients included in the mITT populations, respectively (Fig. 1). Details of dose titration and final dose are provided in the Supplementary Results. Among patients in the mITT population randomized to 5 mg (5-mg
cohort) who completed the study (n=43), 35 (81%) uptitrated to 10 mg at or after Week 12 (53% at or before Week 26) (Supplementary Fig. S2). Among patients assigned to 2 mg (2-mg cohort) who completed the study (n=10), 5 patients each (100%) uptitrated to 5 or 10 mg at or after Week 12 (90% at or before Week 26). A total of 105 patients (88.2%) completed Week 52, 104 of whom rolled over into a long-term extension study. Fourteen (11.8%) patients in the safety population discontinued the study: 6 due to withdrawal of consent, 4 due to adverse events (AEs), 1 due to loss of follow-up, and 3 due to protocol violations.

Patient demographics and baseline disease characteristics in the safety population (N=119) were similar among the treatment cohorts at baseline, although the small number of patients in the 2-mg cohort makes comparisons difficult (Table 1). The majority of patients were female (94.1%) and White (91.6%), and mean age was 57.2 years. Mean PBC duration was 9.7 years, 70.6% of patients had a history of pruritus, 21.0% of patients had cirrhosis, and 6.7% were intolerant to UDCA. Notably, baseline ALP was greater in the 5-mg cohort (345.4 U/L) versus the 2-mg (300.4 U/L) and 10-mg (295.3 U/L) cohorts. Overall, mean total bilirubin levels were 0.8 mg/dL (13.2 µmol/L). Concomitant UDCA was received by 93.2% of patients at a mean daily dose of 15.0 mg/kg. Baseline characteristics in the mITT population were similar to those in the safety population (data not shown).
Efficacy

ALP

At Week 8, mean reductions in ALP from baseline (primary endpoint) were dose dependent: 2-mg (26%), 5-mg (33%), and 10-mg (41%) (Fig. 2A-B). At the end of the dose-ranging period (Week 12), mean ALP levels were significantly (all p≤0.005) reduced from baseline by 68 U/L (23%) in the 2-mg cohort, 136 U/L (35%) in the 5-mg cohort, and 128 U/L (43%) in the 10-mg cohort. Reductions were maintained or continued to decline through Week 52 in the 2-mg (101 U/L [33%]), 5-mg (158 U/L [40%]), and 10-mg (134 U/L [44%]) cohorts (all p≤0.01 versus baseline). ALP reduction was significantly greater in the 10-mg (42%) versus the 2-mg (27%) and 5-mg (33%) cohorts at Week 8 (both p=0.002) and Week 12 (44% versus 23% and 34%, respectively; both p≤0.005) (Supplementary Table S1). Overall, ALP decreased from baseline in the majority of patients at Week 52 (Fig. 2C). ALP normalization was observed in 31% of patients in the 10-mg cohort as early as Week 12 and was maintained at 33% through Week 52 (Fig. 2D). In contrast, in the 2-mg and 5-mg cohorts, normalization occurred in 0% and 11% of patients, respectively, at Week 12 and in 9% and 13%, respectively, at Week 52. Similar results were observed for the ITT population (data not shown).

Composite and published criteria response rates

At Weeks 12 and 52, the composite biochemical response endpoint was achieved by 46% and 64% of patients, respectively, in the 2-mg cohort; 49% and 53%, respectively, in the 5-mg cohort; and 67% in the 10-mg cohort at both time points (Fig. 2E). Responder rates for published PBC response criteria, including the Barcelona, Paris, and Toronto criteria (59 to 79% for 10
mg), were consistent with rates for the composite endpoint (Supplementary Table S2). Additionally, Global PBC Study Group (GLOBE) and United Kingdom–Primary Biliary Cirrhosis (UK-PBC) 5-, 10-, and 15-year risk scores decreased from baseline in a dose-dependent manner at Weeks 12 and 52 (Supplementary Table S3). Main efficacy outcomes for the initial treatment cohorts are summarized in Supplementary Table S4.

The effects of seladelpar among patients randomized to 5 mg QD who remained at this dose (5/5-mg cohort) and those who uptitrated to 10 mg QD after Week 12 (5/10-mg cohort) are summarized in Supplementary Table S5. Mean absolute and relative reductions from baseline in ALP were observed in both cohorts at Weeks 12 and 52 and were significant in both cohorts at both time points (all p≤0.04), except for the 5/5-mg cohort at Week 12. The proportions of patients achieving ALP normalization or the composite endpoint were greater in the 5/5-mg cohort (ie, in patients with an early sustained response not requiring uptitration). In contrast, patients in the 5/10-mg cohort had higher baseline ALP and smaller absolute and relative changes in ALP, which resulted in lower normalization and composite response rates.

Bilirubin, ALT, GGT, AST, and 5’-nucleotidase

Mean changes from baseline in biochemical parameters are summarized in Supplementary Table S1. Mean total and direct bilirubin levels remained stable through Week 52 in all cohorts (Fig. 3A-D). Mean reductions in ALT from baseline differed according to dose at Week 12 (6 U/L [11%], 11 U/L [17%], and 11 U/L [22%], respectively) but coalesced to similar values at Week 52 (14 to 17 U/L [25% to 31%]) (Fig. 4A-B). Similarly, at Week 12, decreases from baseline in GGT were 44 U/L (20%), 75 U/L (29%), and 81 U/L (34%) in the 2-mg, 5-mg, and
10-mg cohorts, respectively. Decreases ranged from 79 to 91 U/L (32% to 34%) at Week 52 (Fig. 4C-D).

Small decreases from baseline in mean AST levels (3 U/L [9%] at Week 12 and 6 U/L [14%] at Week 52) were observed in the 10-mg cohort (Supplementary Fig. S3A-B). Mean AST levels were slightly decreased from baseline in the 2-mg and 5-mg cohorts at Week 12 (3 U/L [4%] and 1 U/L [3%], respectively), with greater decreases from baseline observed at Week 52 in both cohorts (7 U/L [16%] and 6 U/L [13%], respectively). In all cohorts, 5'-nucleotidase levels decreased 23% to 30% from baseline at Weeks 12 and 52 (Supplementary Fig. S3C-D).

Lipids

Mean changes from baseline in lipids are summarized in Supplementary Table S2. High-density lipoprotein cholesterol (HDL-C) levels were maintained or increased through Week 52, while overall other lipids were modestly decreased from baseline in all cohorts (Supplementary Fig. S4A-H). Mean triglyceride levels were decreased by 11 to 23 mg/dL (0.12 to 0.26 mmol/L; 13% to 14%) in all cohorts at Week 12 and by 18 to 25 mg/dL (0.20 to 0.28 mmol/L; 14% to 19%) at Week 52 (Supplementary Fig. S4A-B). Mean low-density lipoprotein cholesterol (LDL-C) levels were also decreased from baseline in the 2-mg, 5-mg, and 10-mg cohorts at Week 12 (3 mg/dL [0.08 mmol/L; 1%], 15 mg/dL [0.39 mmol/L; 9%], and 13 mg/dL [0.34 mmol/L; 8%], respectively) and Week 52 (10 mg/dL [0.26 mmol/L; 6%], 16 mg/dL [0.41 mmol/L; 10%] and 27 mg/dL [0.70 mmol/L; 17%], respectively) (Supplementary Fig. S4C-D).
**C4 and FGF19**

At Week 12, median levels of the bile acid precursor, C4, were decreased from baseline by 4.5 ng/mL in the 5-mg cohort, and 7.2 ng/mL in the 10-mg cohorts, and increased by 2.5 ng/mL in the 2-mg cohort (Fig. 5A). At Week 52, median levels of FGF19 were decreased from baseline by 17%, 6%, and 15% in the 2-mg, 5-mg, and 10-mg cohorts, respectively (Fig. 5B).

**Pruritus VAS score**

Mean pruritus VAS scores were decreased from baseline in all cohorts at Week 12: by 4 mm in the 2-mg cohort, 6 mm in the 5-mg cohort, and 12 mm in the 10-mg cohort (Fig. 6). At Week 52, mean VAS scores decreased further from baseline by 10 mm in the 5-mg cohort and 17 mm in the 10-mg cohort, but the initial decrease (3 mm) in the 2-mg cohort remained stable.

**Safety**

Overall, 105 (88.2%) of the 119 patients treated with seladelpar had TEAEs, with similar incidences across cohorts (Table 2). The overall incidences of treatment-related TEAEs, Grade ≥3 TEAEs, and serious TEAEs (SAEs) were 35.3%, 11.8%, and 11.8%, respectively. These incidences were also similar across cohorts. The most common (≥10%) TEAEs were pruritus (24.4%), diarrhea (16.8%), nausea (16.0%), fatigue (15.1%), urinary tract infection (14.3%), abdominal pain upper (13.4%), nasopharyngitis (12.6%), arthralgia (11.8%), and vomiting (10.1%). Among the 29 patients who experienced pruritus, 18 had a history of pruritus. No patient experienced treatment-related SAEs, and no deaths or clinically meaningful changes in vital signs were reported during the study.
Four patients (3 in the 5-mg cohort and 1 in the 10-mg cohort) discontinued seladelpar due to TEAEs. The TEAEs leading to study drug discontinuation were gastroesophageal reflux (Grade 1, adjudicated as possibly related to seladelpar), pruritus (Grade 1, adjudicated as related to underlying PBC and unrelated to seladelpar), pneumonia (Grade 3, adjudicated as unrelated to seladelpar), and increases in ALT and AST levels (Grades 2 and 3, respectively, concomitant with rifampicin use and adjudicated as possibly related to either seladelpar or rifampicin).

Transient increases in bilirubin unrelated to seladelpar were noted in 2 patients, 1 patient had increased ALT concomitant with worsening of rheumatoid arthritis and use of ibuprofen, and 2 patients experienced ALT and AST elevations concomitant with rifampicin administration for pruritus. Of these latter patients with ALT/AST elevations, both were cirrhotic at baseline, one discontinued the study due to Grade 1 ALT and Grade 2 AST elevations after 23 weeks of treatment, and the other completed the study after aminotransferase elevations (Grade 2) resolved. There were 4 patients who experienced creatinine kinase >2.5×ULN, but all had a clinical explanation (see Supplementary Safety) and/or return to within normal limits while on study drug. Four patients had transient increases in amylase or lipase that were not considered clinically significant. No patients had concerning changes in serum creatinine or other renal markers.

**Efficacy and Safety in Patients With Cirrhosis**

In a prespecified subgroup analysis of patients with and without clinically documented cirrhosis at baseline, reductions in ALP, total bilirubin, and ALT were generally similar between groups at Weeks 12 and 52 (Supplementary Table S6). In the 10-mg cohort, at Week 52, ALP was reduced by 48.5% in patients with (n=9) and 43.2% in patients without cirrhosis (n=40). The
reduction in ALP was smaller in patients with cirrhosis in the 5-mg cohort (n=13) at both time points, although mean baseline ALP was also lower in this subgroup. Safety results were similar in patients with and without cirrhosis (Supplementary Table S7).

DISCUSSION

This study demonstrates the significant anticholestatic effects of seladelpar in patients with PBC who had suboptimally responded to UDCA or were UDCA intolerant. Evidence of seladelpar’s dose-dependent efficacy, safety, and improvement in patient-reported pruritus was substantial and durable. Biochemical improvement and safety were generally similar in patients with and without cirrhosis. Significant reductions in mean ALP levels were observed in all cohorts as early as 3 months, with a 43% reduction from baseline and normalization of ALP in 31% of patients in the 10-mg cohort. ALP reductions, an evidence-based surrogate for long-term transplant-free outcomes\(^9-11\), were maintained through 1 year in patients in the 10-mg cohort. In the 2-mg and 5-mg cohorts, greater reductions in ALP levels from baseline and greater rates of ALP normalization were observed at Week 52 after up titration of dose. The clinically significant, durable effects of the seladelpar 10-mg dose on ALP levels, the composite biochemical response endpoint, and ALP normalization strongly suggest that this dose is optimal for the majority of patients with PBC who have not adequately responded to UDCA or are UDCA intolerant.

The high response rate (53% to 67% at Week 52) observed in this study, based on the composite biochemical endpoint and confirmed by similarity with response rates of published PBC response criteria, and decreased GLOBE and UK-PBC scores suggest that seladelpar lowers the risk for PBC disease progression. The early sustained reductions of other independent...
biomarkers of cholestasis, including GGT and 5’-nucleotidase, further corroborate the anticholestatic activity of seladelpar.

The reductions in liver biochemical tests, including ALT, AST, and GGT levels suggest that seladelpar effectively improves markers of liver injury. Furthermore, although mean baseline cholesterol levels were modestly elevated in this patient population and about one-third of patients were receiving lipid-lowering medications, seladelpar favorably improved triglyceride and cholesterol levels.

Synthesis of the bile acid precursor, C4, was dose-dependently reduced from baseline, indicating that seladelpar may protect against cholestatic liver injury by reducing production of bile acids through downregulation of bile acid synthesis. In addition, median reductions from baseline in FGF19 levels of approximately 10% were observed in all cohorts through Week 52. Since FGF19 transcription is activated in response to bile acid binding to FXR, these results indicate that seladelpar’s effect on bile acid synthesis is distinct from those of FXR agonists like OCA.

Seladelpar was safe and well tolerated at doses up to 10 mg QD, and the safety profile was similar among treatment cohorts. There were no deaths during the study, and no other serious safety signal was identified for seladelpar at doses up to 10 mg QD. Reversible elevations in aminotransferases were observed in 2 patients, although both patients were cirrhotic at baseline and one was able to continue the study without further issue. Pruritus is among the most common symptom of PBC and significantly reduces quality of life. As expected, pruritus was the most commonly reported TEAE in this open-label study (24.4% of patients). However, investigators concluded that pruritus was possibly related or related to seladelpar in only 8.4% of patients. Importantly, 18 of the 29 patients who reported pruritus had a history of pruritus, and seladelpar
improved pruritus VAS score at Week 52. In analyses reported elsewhere, 58% and 93% of patients in the 5-mg and 10-mg cohorts, respectively, with moderate-to-severe pruritus (VAS ≥40) at baseline had a ≥20-point decrease in pruritus VAS at 1 year. Similar improvements in pruritus, sleep disturbance, and quality of life assessed using 5-D itch and PBC-40 questionnaires were observed in patients treated with seladelpar for 1 year. Overall, these results indicate that seladelpar does not induce pruritus. In contrast, OCA, a currently approved second-line PBC treatment, induces itching in a dose-related manner. Thus, the improvement in pruritus with seladelpar observed in this study appears to be advantageous for patients with PBC.

This study has several limitations that should be kept in mind when interpreting results. First, there was an imbalance in baseline ALP levels among cohorts; however, ALP reductions were compared with baseline, and several biochemical endpoints were evaluated. Second, the criteria for dose uptitration were not standardized, except that uptitration could only be done at or after Week 12. As no patients uptitrated their dose before Week 12, this does not affect comparisons among treatment cohorts at this time point; however, after Week 12, comparisons among treatment cohorts cannot be made. Third, this was not a placebo-controlled study. However, prior placebo-controlled studies in similar patient populations have reported small (<10%) ALP decreases in placebo-treated patients. Finally, multiplicity adjustments were not made for efficacy endpoints. Nominal p-values were provided for descriptive purposes.

In conclusion, among patients with PBC with suboptimal responses to UDCA or UDCA intolerance who have a heightened risk of disease progression, seladelpar demonstrated clinically significant dose-dependent biochemical efficacy, absence of concerning safety signals, and
evidence that it might also improve pruritus. A pivotal phase 3 randomized, placebo-controlled clinical trial is ongoing (NCT04620733).

**Abbreviations**

ALP, alkaline phosphatase; ALT, alanine aminotransferase, AST, aspartate aminotransferase; C4, 7α-hydroxy-4-cholesten-3-one; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; GGT, gamma-glutamyl transferase; GLOBE, Global PBC Study Group; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; LS, least squares; mITT, modified intent-to-treat; OCA, obeticholic acid; LOCF, last observation carried forward; PBC, primary biliary cholangitis; PPAR, peroxisome proliferator-activated receptor; QD, once daily; SAE, serious treatment-emergent adverse event; TEAE, treatment-emergent adverse events; UDCA, ursodeoxycholic acid; UK-PBC, United Kingdom–Primary Biliary Cirrhosis; ULN, upper limit of normal; US, United States; VAS, visual analog scale

**Acknowledgments**

We thank the patients, the investigators, study coordinators, and staff who participated in the trial and Holly Capasso-Harris, PhD, and Pragna Bachewal, MS, of Certara Synchrogenix for medical writing assistance.
REFERENCES


### Table 1. Baseline demographics and characteristics (safety population)

<table>
<thead>
<tr>
<th></th>
<th>2 mg (N=11)</th>
<th>5 mg (N=53)</th>
<th>10 mg (N=55)</th>
<th>Total (N=119)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, female, n (%)</strong></td>
<td>11 (100.0)</td>
<td>51 (96.2)</td>
<td>50 (90.9)</td>
<td>112 (94.1)</td>
</tr>
<tr>
<td><strong>Race, White, n (%)</strong></td>
<td>10 (90.9)</td>
<td>50 (94.3)</td>
<td>49 (89.1)</td>
<td>109 (91.6)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>55.2 (9.6)</td>
<td>57.5 (8.1)</td>
<td>57.4 (9.7)</td>
<td>57.2 (9.0)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>29.4 (7.3)</td>
<td>26.6 (5.7)</td>
<td>27.7 (5.3)</td>
<td>27.4 (5.7)</td>
</tr>
<tr>
<td><strong>Duration of PBC (years)</strong></td>
<td>9.3 (6.9)</td>
<td>10.0 (7.0)</td>
<td>9.4 (6.2)</td>
<td>9.7 (6.6)</td>
</tr>
<tr>
<td><strong>Cirrhosis, n (%)</strong></td>
<td></td>
<td>0</td>
<td>14 (26.4)</td>
<td>25 (21.0)</td>
</tr>
<tr>
<td><strong>History of pruritus, n (%)</strong></td>
<td></td>
<td>7 (63.6)</td>
<td>38 (71.7)</td>
<td>84 (70.6)</td>
</tr>
<tr>
<td><strong>ALP (U/L)</strong></td>
<td>300.4 (121.4)</td>
<td>345.4 (188.0)</td>
<td>295.3 (136.0)</td>
<td>318.1 (160.9)</td>
</tr>
<tr>
<td><strong>ALT (U/L)</strong></td>
<td>54.1 (24.6)</td>
<td>46.2 (26.1)</td>
<td>45.8 (22.7)</td>
<td>46.7 (24.3)</td>
</tr>
<tr>
<td><strong>AST (U/L)</strong></td>
<td>45.0 (19.3)</td>
<td>43.2 (20.3)</td>
<td>43.6 (18.7)</td>
<td>43.5 (19.3)</td>
</tr>
<tr>
<td><strong>GGT (U/L)</strong></td>
<td>254.5 (143.3)</td>
<td>234.9 (149.4)</td>
<td>234.3 (192.9)</td>
<td>236.4 (169.2)</td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td>1.1 (0.1)</td>
<td>1.0 (0.1)</td>
<td>1.0 (0.1)</td>
<td>1.0 (0.1)</td>
</tr>
<tr>
<td><strong>Total bilirubin (mg/dL)ᵃ</strong></td>
<td>0.6 (0.1)</td>
<td>0.8 (0.4)</td>
<td>0.8 (0.3)</td>
<td>0.8 (0.3)</td>
</tr>
<tr>
<td><strong>Albumin (g/L)</strong></td>
<td>0.4 (0.02)</td>
<td>0.4 (0.04)</td>
<td>0.4 (0.04)</td>
<td>0.4 (0.03)</td>
</tr>
<tr>
<td><strong>Platelets (×10³/µL)</strong></td>
<td>242.4 (84.2)</td>
<td>214.9 (88.5)</td>
<td>243.5 (74.1)</td>
<td>230.7 (82.3)</td>
</tr>
<tr>
<td><strong>UDCA intolerant, n (%)</strong></td>
<td>0</td>
<td>5 (9.4)</td>
<td>3 (5.5)</td>
<td>8 (6.7)</td>
</tr>
<tr>
<td><strong>Concomitant UDCA, n (%)</strong></td>
<td>11 (100)</td>
<td>48 (90.6)</td>
<td>52 (94.5)</td>
<td>111 (93.2)</td>
</tr>
<tr>
<td><strong>UDCA dose (mg/kg/day), n</strong></td>
<td>11</td>
<td>48</td>
<td>51</td>
<td>110</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>13.6 (4.0)</td>
<td>15.1 (3.2)</td>
<td>15.1 (4.9)</td>
<td>15.0 (4.1)</td>
</tr>
<tr>
<td><strong>Previous treatment with</strong></td>
<td>0</td>
<td>8 (15.1)</td>
<td>7 (12.7)</td>
<td>15 (12.6)</td>
</tr>
<tr>
<td><strong>OCA, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pruritus VAS score, n</strong></td>
<td>11</td>
<td>52</td>
<td>55</td>
<td>118</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>15 (18)</td>
<td>24 (23)</td>
<td>31 (29)</td>
<td>26 (26)</td>
</tr>
<tr>
<td><strong>MELD scoreᵇ, n</strong></td>
<td>11</td>
<td>49</td>
<td>52</td>
<td>NC</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>7.3 (1.3)</td>
<td>6.9 (1.2)</td>
<td>6.9 (1.1)</td>
<td>NC</td>
</tr>
<tr>
<td><strong>Rotterdamᶜ</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Early</strong></td>
<td>11 (100.0)</td>
<td>43 (81.1)</td>
<td>42 (76.4)</td>
<td>96 (80.7)</td>
</tr>
<tr>
<td><strong>Moderately advanced</strong></td>
<td>0</td>
<td>10 (18.9)</td>
<td>11 (20.0)</td>
<td>21 (17.6)</td>
</tr>
<tr>
<td><strong>Advanced</strong></td>
<td>0</td>
<td>0</td>
<td>2 (3.6)</td>
<td>2 (1.7)</td>
</tr>
</tbody>
</table>

Values are mean (SD) unless otherwise noted.

ᵃ Multiply by 17.1 to convert to SI units (µmol/L).

ᵇ MELD score was calculated using the mITT population.
Rotterdam score categories were early (normal total bilirubin and normal albumin), moderately advanced (abnormal albumin OR abnormal total bilirubin), and advanced (abnormal albumin AND abnormal total bilirubin).

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyl transferase; INR, international normalized ratio; MELD, model for end-stage liver disease; mITT, modified intent-to-treat; NC, not calculated; OCA, obeticholic acid; PBC, primary biliary cholangitis; SD, standard deviation; SI, International System of Units; UDCA, ursodeoxycholic acid; VAS, visual analog scale.

Table 2. Summary of treatment-emergent adverse events

<table>
<thead>
<tr>
<th></th>
<th>2 mg (N=11)</th>
<th>5 mg (N=53)</th>
<th>10 mg (N=55)</th>
<th>Total (N=119)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAE</td>
<td>11 (100.0)</td>
<td>47 (88.7)</td>
<td>47 (85.5)</td>
<td>105 (88.2)</td>
</tr>
<tr>
<td>Any treatment-related TEAE</td>
<td>6 (54.5)</td>
<td>21 (39.6)</td>
<td>15 (27.3)</td>
<td>42 (35.3)</td>
</tr>
<tr>
<td>Any Grade ≥3 TEAE</td>
<td>1 (9.1)</td>
<td>8 (15.1)</td>
<td>5 (9.1)</td>
<td>14 (11.8)</td>
</tr>
<tr>
<td>Any serious TEAE</td>
<td>1 (9)</td>
<td>8 (15.1)</td>
<td>5 (9.1)</td>
<td>14 (11.8)</td>
</tr>
<tr>
<td>Deaths</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

TEAEs occurring in ≥10% of patients in any treatment cohort

<table>
<thead>
<tr>
<th></th>
<th>2 mg (N=11)</th>
<th>5 mg (N=53)</th>
<th>10 mg (N=55)</th>
<th>Total (N=119)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pruritus</td>
<td>6 (54.5)</td>
<td>11 (20.8)</td>
<td>12 (21.8)</td>
<td>29 (24.4)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4 (36.4)</td>
<td>7 (13.2)</td>
<td>9 (16.4)</td>
<td>20 (16.8)</td>
</tr>
<tr>
<td>Nausea</td>
<td>4 (36.4)</td>
<td>9 (17.0)</td>
<td>6 (10.9)</td>
<td>19 (16.0)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (27.3)</td>
<td>9 (17.0)</td>
<td>6 (10.9)</td>
<td>18 (15.1)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>1 (9.1)</td>
<td>8 (15.1)</td>
<td>8 (14.5)</td>
<td>17 (14.3)</td>
</tr>
<tr>
<td>Abdominal pain upper</td>
<td>3 (27.3)</td>
<td>8 (15.1)</td>
<td>5 (9.1)</td>
<td>16 (13.4)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>4 (36.4)</td>
<td>5 (9.4)</td>
<td>6 (10.9)</td>
<td>15 (12.6)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>1 (9.1)</td>
<td>6 (11.3)</td>
<td>7 (12.7)</td>
<td>14 (11.8)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>3 (27.3)</td>
<td>4 (7.5)</td>
<td>5 (9.1)</td>
<td>12 (10.1)</td>
</tr>
<tr>
<td>Back pain</td>
<td>3 (27.3)</td>
<td>5 (9.4)</td>
<td>3 (5.5)</td>
<td>11 (9.2)</td>
</tr>
<tr>
<td>Headache</td>
<td>2 (18.2)</td>
<td>6 (11.3)</td>
<td>3 (5.5)</td>
<td>11 (9.2)</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>2 (18.2)</td>
<td>4 (7.5)</td>
<td>4 (7.3)</td>
<td>10 (8.4)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>2 (18.2)</td>
<td>5 (9.4)</td>
<td>3 (5.5)</td>
<td>10 (8.4)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3 (27.3)</td>
<td>3 (5.7)</td>
<td>3 (5.5)</td>
<td>9 (7.6)</td>
</tr>
<tr>
<td>Cough</td>
<td>2 (18.2)</td>
<td>4 (7.5)</td>
<td>3 (5.5)</td>
<td>9 (7.6)</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>2 (18.2)</td>
<td>2 (3.8)</td>
<td>4 (7.3)</td>
<td>8 (6.7)</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>2 (18.2)</td>
<td>1 (1.9)</td>
<td>4 (7.3)</td>
<td>7 (5.9)</td>
</tr>
<tr>
<td>Dry eye</td>
<td>2 (18.2)</td>
<td>1 (1.9)</td>
<td>4 (7.3)</td>
<td>7 (5.9)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>3 (27.3)</td>
<td>2 (3.8)</td>
<td>1 (1.8)</td>
<td>6 (5.0)</td>
</tr>
</tbody>
</table>

All values are n (%).
Adverse events were coded using MedDRA® version 22.0. Patients were included only once, even if they experienced multiple occurrences. MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment-emergent adverse event.

**FIGURE LEGENDS**

**Fig. 1. Patient disposition.** *Per investigator decision, at some point after Week 12, 36 patients randomized to 5 mg uptitrated to 10 mg (5/10-mg cohort) and 17 patients remained at 5 mg (5/5-mg cohort).*

**Fig. 2. Effect of seladelpar on ALP and the composite endpoint through Week 52.** (A) Mean percent change in ALP from BL (imputed using LOCF). (B) Mean absolute ALP values (observed). (C) Change in ALP from BL in individual patients (observed). (D) Proportion of patients achieving ALP normalization (imputed using LOCF). (E) Proportion of patients achieving the composite endpoint (imputed using LOCF). *p≤0.02 versus BL (paired t-test); †p≤0.01 versus 2-mg cohort (ANCOVA test of LS means); ‡p≤0.02 versus 5-mg cohort (ANCOVA test of LS means); §p≤0.03 versus 5-mg cohort (Fisher’s exact test). ALP, alkaline phosphatase; ANCOVA, analysis of covariance; BL, baseline; LOCF, last observation carried forward; LS, least squares; SE, standard error; ULN, upper limit of normal.

**Fig. 3. Effect of seladelpar on total and direct bilirubin through Week 52.** (A) Mean percent change in total bilirubin from BL (observed). (B) Mean absolute total bilirubin values (observed). (C) Mean percent change in direct bilirubin from BL (observed). (D) Mean absolute direct bilirubin values (observed). *Nominal p≤0.02 versus BL (paired t-test). BL, baseline; SE, standard error; ULN, upper limit of normal.
**Fig. 4. Effect of seladelpar on ALT and GGT through Week 52.** (A) Mean percent change in ALT from BL (observed). (B) Mean absolute ALT values (observed). (C) Mean percent change in GGT from BL (observed). (D) Mean absolute GGT values (observed). *Nominal p<0.05 versus BL (paired t-test). ALT, alanine aminotransferase; BL, baseline; GGT, gamma-glutamyl transferase; SE, standard error; ULN, upper limit of normal.

**Fig. 5. Mean percent change in C4 at Week 12 (observed) (A) and mean absolute FGF19 values (observed) through Week 52 (B).** *Nominal p≤0.04 versus BL (paired t-test). BL, baseline; C4, 7α-hydroxy-4-cholesten-3-one; FGF19, fibroblast growth factor 19; SD, standard deviation; SE, standard error.

**Fig. 6. Effect of seladelpar on pruritus VAS through Week 52.** 0=no itch, 100=worst itch imaginable. *Nominal p≤0.009 versus BL (paired t-test). BL, baseline; SE, standard error; VAS, visual analog score.
Patients screened, N = 192

Screen failures, N = 71

Patients assigned to treatment, N = 121

Patients in 2-mg dose group, N = 11

Patients in 5-mg dose group, N = 54

Patients in 10-mg dose group, N = 56

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43

Discontinued, N = 4
  Withdrew informed consent, n = 2
  Lost to follow-up, n = 1
  Protocol violation, n = 1

Patients completing study, N = 48

Discontinued, N = 1
  Withdrew informed consent

Patients completing study, N = 10

Final dose
  2 mg, n = 1
  5 mg, n = 5
  10 mg, n = 5

Discontinued, N = 1
  Withdrew informed consent

Patients not in the mITT population, N = 4
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 3

Final dose for mITT population, N = 52
  2 mg, n = 0
  5 mg, n = 1
  10 mg, n = 51

Discontinued, N = 4
  Withdrew informed consent, n = 2

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43

Discontinued, N = 6
  Withdrew informed consent

Patients not in the mITT population, N = 4
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 3

Final dose for mITT population, N = 52
  2 mg, n = 0
  5 mg, n = 1
  10 mg, n = 51

Discontinued, N = 4
  Withdrew informed consent, n = 2

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43

Discontinued, N = 6
  Withdrew informed consent

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43

Discontinued, N = 6
  Withdrew informed consent

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43

Discontinued, N = 6
  Withdrew informed consent

Patients not in the mITT population, N = 5
  Did not receive treatment, n = 1
  PBC diagnosis not confirmed, n = 4

Final dose for mITT population, N = 49
  2 mg, n = 2
  5 mg, n = 17
  10 mg, n = 30

Discontinued, N = 6
  Adverse events, n = 3
  Withdrew informed consent, n = 3

Patients completing study, N = 43
Mean (SE) change in pruritis VAS

<table>
<thead>
<tr>
<th>Dose</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg</td>
<td>-10</td>
<td>-20</td>
<td>-30</td>
<td>-40</td>
<td>-50</td>
</tr>
<tr>
<td>5 mg</td>
<td>-5</td>
<td>-10</td>
<td>-15</td>
<td>-20</td>
<td>-25</td>
</tr>
<tr>
<td>10 mg</td>
<td>0</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
</tr>
</tbody>
</table>

**Stable Doses**  
**Dose Upliftation Permitted**

* *
HIGHLIGHTS

- Seladelpar (2, 5, 10 mg) was assessed in patients with primary biliary cholangitis
- Alkaline phosphatase (ALP) was dose-dependently reduced by 23% to 43% at Week 12
- ALP was normalized in 33% of patients in the 10-mg cohort at Week 52
- Up to 67% of patients met the composite ALP and bilirubin endpoint at Week 52
- Seladelpar was safe, with no treatment-related serious adverse events or deaths